Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Abeona Therapeutics Inc. Common Stock

ABEO

Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.

Last trade $2.59
Day change -$0.015 (-0.58%)
Day range $2.49 – $2.77
Volume 987,249
Market cap $160M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$160.27M
Price / earnings
—
Price / book
1.27×
Price / sales
4.11×
EV / sales
2.71×
EV / EBITDA
-1.52×

Profitability

Earnings per share
-$1.01
Return on assets
-36.37%
Return on equity
-49.68%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.09×
Current ratio
5.69×
Quick ratio
5.52×
Cash ratio
2.39×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$66.35M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for ABEO, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$13.49M$11.38M$8.72M$5.42M$0$400K$0$0
Cost of revenue$5.71M$4.18M$2.7M$1.04M$488K$0$0$0
Gross profit$7.78M$7.2M$6.02M$4.38M-$488K$400K$0$0
Selling, general and administrative$17.11M$15.84M$19.5M$18.78M$19.31M$17.15M$9.79M$7.68M
Research and development$3.67M$5.02M$9.56M$6.71M$4.22M$5.94M$9.94M$8.99M
Total operating expenses$20.78M$20.86M$29.06M$27.29M$23.53M$23.19M$19.73M$16.67M
Operating income-$13M-$13.65M-$23.03M-$22.91M-$24.02M-$22.79M-$19.73M-$16.67M
Interest expense-$557K-$696K-$830K-$884K-$901K-$957K-$998K-$1.08M
Income before taxes-$4.79M-$20.19M-$17.07M-$20.68M-$20.36M$124.35M-$12.03M-$9.29M
Income taxes$18K$0$2K-$215K-$15.2M$15.51M$0$0
Net income-$4.81M-$20.19M-$17.08M-$20.46M-$5.16M$108.83M-$12.03M-$9.29M
Net income attributable to common shareholders-$4.81M-$20.19M-$17.08M-$20.46M-$5.16M$108.83M-$12.03M-$9.29M
EBITDA-$12.3M-$12.99M-$22.34M-$22.05M-$23.41M-$22.25M-$19.19M-$16.13M
Basic earnings per share-$0.08-$0.35-$0.30-$0.37-$0.10$2.07-$0.24-$0.19
Diluted earnings per share-$0.08-$0.35-$0.30-$0.22-$0.10$1.71-$0.24-$0.25

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO

Pomerantz LLP announced investigations into potential securities fraud at Abeona Therapeutics following disclosure that only 4 of 5 ZEVASKYN treatments were recognized for revenue due to one batch lacking minimum sheet requirements. The stock fell 14.95% to $6.35 on August 13, 2026. Similar investigations were initiated for JinkoSolar and Stitch Fix.

GlobeNewswire Inc.

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Babcock & Wilcox Enterprises, Inc. of Class Action Lawsuit - BW

Pomerantz Law Firm has filed class action lawsuits against Babcock & Wilcox Enterprises, Inc. (BW) on behalf of investors who acquired securities between November 5, 2025, and March 11, 2026. The firm is also investigating claims on behalf of investors in Abeona Therapeutics Inc. (ABEO) and has announced a class action lawsuit against AST SpaceMobile, Inc. (ASTS) and certain officers.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jul 5, 20221-for-25reverse split